Yang Chun-Ting, Wilkins James M, DiCesare Elyse, Pritchard Kevin T, Chen Qiaoxi, Zhang Yichi, Kim Dae Hyun, Lin Kueiyu Joshua
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Boston, Massachusetts.
JAMA Psychiatry. 2025 May 14. doi: 10.1001/jamapsychiatry.2025.0702.
Among hospitalized older adults, prolonged use of antipsychotic medications (APMs) following hospital discharge may increase the risk of APM-associated adverse events. There are limited data on whether early discontinuation of APMs is associated with reduced adverse clinical outcomes compared with APM continuation after discharge.
To compare clinical outcomes between discontinuation vs continuation of APMs initiated to manage hospitalization-related delirium.
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study examining nationwide US Medicare claims data from July 1, 2013, through December 31, 2018, and data from a large deidentified US commercial health care database (Optum CDM) from July 1, 2004, through May 31, 2024, included adults aged 65 years and older without psychiatric disorders or previous use of APMs who filled an APM prescription within 30 days of hospital discharge. Using incidence density sampling, APM discontinuers (gap ≥45 days) were matched with continuers based on the type of APM prescribed, the time since their first APM prescription, and whether they had been admitted to intensive care units prior to the first APM prescription. Data analysis was performed from July 12, 2024, to December 25, 2024.
Discontinuation vs continuation of APMs.
Propensity score matching was applied to adjust for 162 covariates. Study outcomes included rehospitalization, specific rehospitalization reasons, and all-cause mortality. Hazard ratios (HRs) were estimated using the Cox proportional hazards model; estimates from the 2 databases were further pooled using the fixed-effects meta-analysis model.
A total of 13 712 propensity score-matched pairs were included, for an overall sample of 27 424 adults (discontinuers: mean [SD] age, 81.86 [7.26] years; 7400 [54.0%] female; continuers: mean [SD] age, 81.86 [7.27] years; 7360 [53.7%] female). During the median (IQR) follow-up of 180 (87-180) days, APM discontinuation vs continuation was associated with significantly lower risks of rehospitalization (HR, 0.89 [95% CI, 0.85-0.94]), inpatient delirium (HR, 0.87 [95% CI, 0.79-0.96]), fall-related emergency department visits or hospitalizations (HR, 0.77 [95% CI, 0.67-0.90]), hospitalization with urinary tract infection (HR, 0.79 [95% CI, 0.66-0.94]), and all-cause mortality (HR, 0.77 [95% CI, 0.69-0.86]). There was no statistical difference in the risks of pneumonia (HR, 0.88 [95% CI, 0.73-1.06]) or stroke (HR, 1.22 [95% CI, 0.97-1.53]) between discontinuers and continuers. Subgroups by dementia status, type and dose of APM prescribed, and duration of APM exposure showed consistent results.
Based on 2 nationwide US cohorts including older adults without psychiatric disorders, APM discontinuation was associated with reduced risks of all-cause rehospitalization and mortality, suggesting the importance of minimizing the duration of APM use after acute hospitalization.
在住院的老年人中,出院后长期使用抗精神病药物(APM)可能会增加与APM相关的不良事件风险。与出院后继续使用APM相比,早期停用APM是否与不良临床结局的减少相关的数据有限。
比较为管理与住院相关的谵妄而启动的APM停用与继续使用的临床结局。
设计、设置和参与者:这项基于人群的队列研究分析了2013年7月1日至2018年12月31日期间美国全国医疗保险索赔数据,以及2004年7月1日至2024年5月31日期间来自美国一个大型匿名商业医疗保健数据库(Optum CDM)的数据,纳入了65岁及以上、无精神疾病或既往未使用过APM且在出院后30天内开具APM处方的成年人。采用发病密度抽样,根据所开具APM的类型、首次APM处方后的时间以及首次APM处方前是否入住过重症监护病房,将APM停用者(间隔≥45天)与继续使用者进行匹配。数据分析于2024年7月12日至2024年12月25日进行。
APM的停用与继续使用。
应用倾向得分匹配法调整162个协变量。研究结局包括再次住院、特定的再次住院原因和全因死亡率。使用Cox比例风险模型估计风险比(HR);来自两个数据库的估计值进一步使用固定效应荟萃分析模型进行汇总。
共纳入13712对倾向得分匹配的对象,总样本为27424名成年人(停用者:平均[标准差]年龄,81.86[7.26]岁;7400名[54.0%]为女性;继续使用者:平均[标准差]年龄,81.86[7.27]岁;7360名[53.7%]为女性)。在180(87 - 180)天的中位(四分位间距)随访期间,与继续使用APM相比,停用APM与再次住院风险显著降低相关(HR,0.89[95%置信区间,0.85 - 0.94])、住院期间谵妄(HR,0.87[95%置信区间,0.79 - 0.96])、与跌倒相关的急诊科就诊或住院(HR,0.77[95%置信区间,0.67 - 0.90])、因尿路感染住院(HR,0.79[95%置信区间,0.66 - 0.94])以及全因死亡率(HR,0.77[95%置信区间,0.69 - 0.86])显著降低相关。停用者和继续使用者在肺炎(HR,0.88[95%置信区间,0.73 - 1.06])或中风(HR,1.22[95%置信区间,0.97 - 1.53])风险方面无统计学差异。按痴呆状态、所开具APM的类型和剂量以及APM暴露持续时间划分的亚组显示出一致的结果。
基于包括无精神疾病的老年人在内的两个美国全国性队列,停用APM与全因再次住院和死亡风险降低相关,这表明在急性住院后尽量缩短APM使用时间的重要性。